BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Vancouver - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinvancouver.com
X-WR-CALDESC:Events for Science in Vancouver
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210929T120000
DTEND;TZID=America/Vancouver:20210929T130000
DTSTAMP:20260406T072721
CREATED:20210903T173120Z
LAST-MODIFIED:20210903T173120Z
UID:18160-1632916800-1632920400@scienceinvancouver.com
SUMMARY:UBC's Annual Address: Powering Bio-Innovation in British Columbia
DESCRIPTION:We are entering a golden age of biomedical discovery\, where new classes of therapeutics—such as mRNA\, gene\, and cell therapies—are expected to transform human health and drive economic growth over the next century. With world-class biomedical researchers and a vibrant life sciences ecosystem\, B.C. has a tremendous opportunity to lead this global transformation and shape a more healthy\, sustainable and innovative future for British Columbia. \nThis panel of UBC experts and B.C. business leaders will explore the critical role that bio-innovation will play in British Columbia’s economic and social prosperity\, and what is needed to strengthen the overall ecosystem\, from research and talent development to commercialization. \nPANELLISTS\n\n\n\n         \n\n\n\nDr. Anna Blakney\, Assistant Professor\, Michael Smith Laboratories and School of Biomedical Engineering\, University of British Columbia\nKarimah Es Sabar\, CEO & Partner\, Quark Venture LP\nDr. Dermot Kelleher\, Professor\, Department of Medicine; Dean\, Faculty of Medicine; Vice-President\, Health\, University of British Columbia\nModerator: Professor Santa J. Ono\, President and Vice-Chancellor\, University of British Columbia \nAdditional panelists to be announced
URL:https://scienceinvancouver.com/event/ubcs-annual-address-powering-bio-innovation-in-british-columbia/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210929T120000
DTEND;TZID=America/Vancouver:20210929T130000
DTSTAMP:20260406T072721
CREATED:20210903T173120Z
LAST-MODIFIED:20210903T173120Z
UID:26429-1632916800-1632920400@scienceinvancouver.com
SUMMARY:UBC's Annual Address: Powering Bio-Innovation in British Columbia
DESCRIPTION:We are entering a golden age of biomedical discovery\, where new classes of therapeutics—such as mRNA\, gene\, and cell therapies—are expected to transform human health and drive economic growth over the next century. With world-class biomedical researchers and a vibrant life sciences ecosystem\, B.C. has a tremendous opportunity to lead this global transformation and shape a more healthy\, sustainable and innovative future for British Columbia. \nThis panel of UBC experts and B.C. business leaders will explore the critical role that bio-innovation will play in British Columbia’s economic and social prosperity\, and what is needed to strengthen the overall ecosystem\, from research and talent development to commercialization. \nPANELLISTS\n\n\n\n         \n\n\n\nDr. Anna Blakney\, Assistant Professor\, Michael Smith Laboratories and School of Biomedical Engineering\, University of British Columbia\nKarimah Es Sabar\, CEO & Partner\, Quark Venture LP\nDr. Dermot Kelleher\, Professor\, Department of Medicine; Dean\, Faculty of Medicine; Vice-President\, Health\, University of British Columbia\nModerator: Professor Santa J. Ono\, President and Vice-Chancellor\, University of British Columbia \nAdditional panelists to be announced
URL:https://scienceinvancouver.com/event/ubcs-annual-address-powering-bio-innovation-in-british-columbia-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210929T120000
DTEND;TZID=America/Vancouver:20210929T130000
DTSTAMP:20260406T072721
CREATED:20210903T173120Z
LAST-MODIFIED:20210903T173120Z
UID:28044-1632916800-1632920400@scienceinvancouver.com
SUMMARY:UBC's Annual Address: Powering Bio-Innovation in British Columbia
DESCRIPTION:We are entering a golden age of biomedical discovery\, where new classes of therapeutics—such as mRNA\, gene\, and cell therapies—are expected to transform human health and drive economic growth over the next century. With world-class biomedical researchers and a vibrant life sciences ecosystem\, B.C. has a tremendous opportunity to lead this global transformation and shape a more healthy\, sustainable and innovative future for British Columbia. \nThis panel of UBC experts and B.C. business leaders will explore the critical role that bio-innovation will play in British Columbia’s economic and social prosperity\, and what is needed to strengthen the overall ecosystem\, from research and talent development to commercialization. \nPANELLISTS\n\n\n\n         \n\n\n\nDr. Anna Blakney\, Assistant Professor\, Michael Smith Laboratories and School of Biomedical Engineering\, University of British Columbia\nKarimah Es Sabar\, CEO & Partner\, Quark Venture LP\nDr. Dermot Kelleher\, Professor\, Department of Medicine; Dean\, Faculty of Medicine; Vice-President\, Health\, University of British Columbia\nModerator: Professor Santa J. Ono\, President and Vice-Chancellor\, University of British Columbia \nAdditional panelists to be announced
URL:https://scienceinvancouver.com/event/ubcs-annual-address-powering-bio-innovation-in-british-columbia-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210929T120000
DTEND;TZID=America/Vancouver:20210929T130000
DTSTAMP:20260406T072721
CREATED:20210903T173120Z
LAST-MODIFIED:20210903T173120Z
UID:31127-1632916800-1632920400@scienceinvancouver.com
SUMMARY:UBC's Annual Address: Powering Bio-Innovation in British Columbia
DESCRIPTION:We are entering a golden age of biomedical discovery\, where new classes of therapeutics—such as mRNA\, gene\, and cell therapies—are expected to transform human health and drive economic growth over the next century. With world-class biomedical researchers and a vibrant life sciences ecosystem\, B.C. has a tremendous opportunity to lead this global transformation and shape a more healthy\, sustainable and innovative future for British Columbia. \nThis panel of UBC experts and B.C. business leaders will explore the critical role that bio-innovation will play in British Columbia’s economic and social prosperity\, and what is needed to strengthen the overall ecosystem\, from research and talent development to commercialization. \nPANELLISTS\n\n\n\n         \n\n\n\nDr. Anna Blakney\, Assistant Professor\, Michael Smith Laboratories and School of Biomedical Engineering\, University of British Columbia\nKarimah Es Sabar\, CEO & Partner\, Quark Venture LP\nDr. Dermot Kelleher\, Professor\, Department of Medicine; Dean\, Faculty of Medicine; Vice-President\, Health\, University of British Columbia\nModerator: Professor Santa J. Ono\, President and Vice-Chancellor\, University of British Columbia \nAdditional panelists to be announced
URL:https://scienceinvancouver.com/event/ubcs-annual-address-powering-bio-innovation-in-british-columbia-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210929T120000
DTEND;TZID=America/Vancouver:20210929T130000
DTSTAMP:20260406T072721
CREATED:20210903T173120Z
LAST-MODIFIED:20210903T173120Z
UID:32587-1632916800-1632920400@scienceinvancouver.com
SUMMARY:UBC's Annual Address: Powering Bio-Innovation in British Columbia
DESCRIPTION:We are entering a golden age of biomedical discovery\, where new classes of therapeutics—such as mRNA\, gene\, and cell therapies—are expected to transform human health and drive economic growth over the next century. With world-class biomedical researchers and a vibrant life sciences ecosystem\, B.C. has a tremendous opportunity to lead this global transformation and shape a more healthy\, sustainable and innovative future for British Columbia. \nThis panel of UBC experts and B.C. business leaders will explore the critical role that bio-innovation will play in British Columbia’s economic and social prosperity\, and what is needed to strengthen the overall ecosystem\, from research and talent development to commercialization. \nPANELLISTS\n\n\n\n         \n\n\n\nDr. Anna Blakney\, Assistant Professor\, Michael Smith Laboratories and School of Biomedical Engineering\, University of British Columbia\nKarimah Es Sabar\, CEO & Partner\, Quark Venture LP\nDr. Dermot Kelleher\, Professor\, Department of Medicine; Dean\, Faculty of Medicine; Vice-President\, Health\, University of British Columbia\nModerator: Professor Santa J. Ono\, President and Vice-Chancellor\, University of British Columbia \nAdditional panelists to be announced
URL:https://scienceinvancouver.com/event/ubcs-annual-address-powering-bio-innovation-in-british-columbia-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211001T120000
DTEND;TZID=America/Vancouver:20211001T130000
DTSTAMP:20260406T072721
CREATED:20210921T205457Z
LAST-MODIFIED:20210921T205457Z
UID:18434-1633089600-1633093200@scienceinvancouver.com
SUMMARY:Studying KT: Career Paths for Researchers and Trainees
DESCRIPTION:Are you a researcher or a trainee interested in building or advancing your career in KT research? Are you curious about tools and resources available to support your KT journey? Want to learn more about the competencies required for a KT career? We are here to help! \nJoin us for a special KT Connects panel series (part 1) on “Studying KT: Career paths for researchers and trainees” as our esteemed guests share their tips\, experiences and resources to help build your career in KT research! \nSpeakers:\nDr. Clayon Hamilton – Regional Practice Lead\, Fraser Health & Adjunct Professor\, Simon Fraser University\nDr. Jasmin Ma – Assistant Professor\, University of British Columbia\nDr. Lupin Battersby – Knowledge Mobilization Officer\, Simon Fraser University\nDr. Lynne Freehan – Knowledge Translation Lead\, BC SUPPORT Unit & Clinical Associate Professor\, University of British Columbia \nPlease share any questions/topics you would like our speakers to cover during the session via email (KT@msfhr.org) or the webinar registration page. Please note you will also have the opportunity to ask questions during the Q&A period!
URL:https://scienceinvancouver.com/event/studying-kt-career-paths-for-researchers-and-trainees/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211001T120000
DTEND;TZID=America/Vancouver:20211001T130000
DTSTAMP:20260406T072721
CREATED:20210921T205457Z
LAST-MODIFIED:20210921T205457Z
UID:26441-1633089600-1633093200@scienceinvancouver.com
SUMMARY:Studying KT: Career Paths for Researchers and Trainees
DESCRIPTION:Are you a researcher or a trainee interested in building or advancing your career in KT research? Are you curious about tools and resources available to support your KT journey? Want to learn more about the competencies required for a KT career? We are here to help! \nJoin us for a special KT Connects panel series (part 1) on “Studying KT: Career paths for researchers and trainees” as our esteemed guests share their tips\, experiences and resources to help build your career in KT research! \nSpeakers:\nDr. Clayon Hamilton – Regional Practice Lead\, Fraser Health & Adjunct Professor\, Simon Fraser University\nDr. Jasmin Ma – Assistant Professor\, University of British Columbia\nDr. Lupin Battersby – Knowledge Mobilization Officer\, Simon Fraser University\nDr. Lynne Freehan – Knowledge Translation Lead\, BC SUPPORT Unit & Clinical Associate Professor\, University of British Columbia \nPlease share any questions/topics you would like our speakers to cover during the session via email (KT@msfhr.org) or the webinar registration page. Please note you will also have the opportunity to ask questions during the Q&A period!
URL:https://scienceinvancouver.com/event/studying-kt-career-paths-for-researchers-and-trainees-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211001T120000
DTEND;TZID=America/Vancouver:20211001T130000
DTSTAMP:20260406T072721
CREATED:20210921T205457Z
LAST-MODIFIED:20210921T205457Z
UID:28055-1633089600-1633093200@scienceinvancouver.com
SUMMARY:Studying KT: Career Paths for Researchers and Trainees
DESCRIPTION:Are you a researcher or a trainee interested in building or advancing your career in KT research? Are you curious about tools and resources available to support your KT journey? Want to learn more about the competencies required for a KT career? We are here to help! \nJoin us for a special KT Connects panel series (part 1) on “Studying KT: Career paths for researchers and trainees” as our esteemed guests share their tips\, experiences and resources to help build your career in KT research! \nSpeakers:\nDr. Clayon Hamilton – Regional Practice Lead\, Fraser Health & Adjunct Professor\, Simon Fraser University\nDr. Jasmin Ma – Assistant Professor\, University of British Columbia\nDr. Lupin Battersby – Knowledge Mobilization Officer\, Simon Fraser University\nDr. Lynne Freehan – Knowledge Translation Lead\, BC SUPPORT Unit & Clinical Associate Professor\, University of British Columbia \nPlease share any questions/topics you would like our speakers to cover during the session via email (KT@msfhr.org) or the webinar registration page. Please note you will also have the opportunity to ask questions during the Q&A period!
URL:https://scienceinvancouver.com/event/studying-kt-career-paths-for-researchers-and-trainees-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211001T120000
DTEND;TZID=America/Vancouver:20211001T130000
DTSTAMP:20260406T072721
CREATED:20210921T205457Z
LAST-MODIFIED:20210921T205457Z
UID:31139-1633089600-1633093200@scienceinvancouver.com
SUMMARY:Studying KT: Career Paths for Researchers and Trainees
DESCRIPTION:Are you a researcher or a trainee interested in building or advancing your career in KT research? Are you curious about tools and resources available to support your KT journey? Want to learn more about the competencies required for a KT career? We are here to help! \nJoin us for a special KT Connects panel series (part 1) on “Studying KT: Career paths for researchers and trainees” as our esteemed guests share their tips\, experiences and resources to help build your career in KT research! \nSpeakers:\nDr. Clayon Hamilton – Regional Practice Lead\, Fraser Health & Adjunct Professor\, Simon Fraser University\nDr. Jasmin Ma – Assistant Professor\, University of British Columbia\nDr. Lupin Battersby – Knowledge Mobilization Officer\, Simon Fraser University\nDr. Lynne Freehan – Knowledge Translation Lead\, BC SUPPORT Unit & Clinical Associate Professor\, University of British Columbia \nPlease share any questions/topics you would like our speakers to cover during the session via email (KT@msfhr.org) or the webinar registration page. Please note you will also have the opportunity to ask questions during the Q&A period!
URL:https://scienceinvancouver.com/event/studying-kt-career-paths-for-researchers-and-trainees-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211001T120000
DTEND;TZID=America/Vancouver:20211001T130000
DTSTAMP:20260406T072721
CREATED:20210921T205457Z
LAST-MODIFIED:20210921T205457Z
UID:32599-1633089600-1633093200@scienceinvancouver.com
SUMMARY:Studying KT: Career Paths for Researchers and Trainees
DESCRIPTION:Are you a researcher or a trainee interested in building or advancing your career in KT research? Are you curious about tools and resources available to support your KT journey? Want to learn more about the competencies required for a KT career? We are here to help! \nJoin us for a special KT Connects panel series (part 1) on “Studying KT: Career paths for researchers and trainees” as our esteemed guests share their tips\, experiences and resources to help build your career in KT research! \nSpeakers:\nDr. Clayon Hamilton – Regional Practice Lead\, Fraser Health & Adjunct Professor\, Simon Fraser University\nDr. Jasmin Ma – Assistant Professor\, University of British Columbia\nDr. Lupin Battersby – Knowledge Mobilization Officer\, Simon Fraser University\nDr. Lynne Freehan – Knowledge Translation Lead\, BC SUPPORT Unit & Clinical Associate Professor\, University of British Columbia \nPlease share any questions/topics you would like our speakers to cover during the session via email (KT@msfhr.org) or the webinar registration page. Please note you will also have the opportunity to ask questions during the Q&A period!
URL:https://scienceinvancouver.com/event/studying-kt-career-paths-for-researchers-and-trainees-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T093000
DTEND;TZID=America/Vancouver:20211007T110000
DTSTAMP:20260406T072721
CREATED:20211004T165740Z
LAST-MODIFIED:20211004T165740Z
UID:18631-1633599000-1633604400@scienceinvancouver.com
SUMMARY:Blakes Breakfast Speaking Series
DESCRIPTION:A new class of drugs is emerging to expand the spectrum of treatments for cancer\, called radiopharmaceuticals\, which deliver radiation directly and specifically to cancer cells.  These drugs contain radioactive isotopes and can be used as both diagnostic and therapeutic agents. \nTargeting radiation therapy at the cellular level has the potential to reduce the risk of both short-term and long-term side effects of treatment\, while proving effective at killing even the small clusters of cancer cells throughout the body. \nReduced side effects and precision delivery are driving the interest and high growth in this new generation of radiopharmaceuticals. A number of new therapies are emerging\, including using lutetium-177 to treat prostate and neuroendocrine cancers. The global market for radiopharmaceuticals was estimated at $6.1 billion in 2019\, and is projected to reach $12.6 billion by 2027. \nThe Blakes Breakfast Speaking Series is our longest-standing event series and one of our most popular. These breakfasts include presentations by local\, national\, and multinational life science companies and typically attract a cross-section of approximately 75 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake\, Cassels & Graydon LLP. \nSpeakers:\n\nNoël Brown\, Managing Director & Head of U.S. Biotechnology Investment Banking\, RBC Capital Markets\nKathryn Hayashi\, President & CEO\, TRIUMF Innovations\nDr. Lana Janes\, Venture Partner at adMare BioInnovations\, Interim CEO at Abdera Therapeutics\nCody Shirriff\, CEO & Founder\, Serenity Bioworks\n\nEvent Details:\nDate: October 7\, 2021 \nTime: 9:30 AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/blakes-breakfast-speaking-series/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Blakes-Breakfast-Main-Image-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T093000
DTEND;TZID=America/Vancouver:20211007T110000
DTSTAMP:20260406T072721
CREATED:20211004T165740Z
LAST-MODIFIED:20211004T165740Z
UID:26443-1633599000-1633604400@scienceinvancouver.com
SUMMARY:Blakes Breakfast Speaking Series
DESCRIPTION:A new class of drugs is emerging to expand the spectrum of treatments for cancer\, called radiopharmaceuticals\, which deliver radiation directly and specifically to cancer cells.  These drugs contain radioactive isotopes and can be used as both diagnostic and therapeutic agents. \nTargeting radiation therapy at the cellular level has the potential to reduce the risk of both short-term and long-term side effects of treatment\, while proving effective at killing even the small clusters of cancer cells throughout the body. \nReduced side effects and precision delivery are driving the interest and high growth in this new generation of radiopharmaceuticals. A number of new therapies are emerging\, including using lutetium-177 to treat prostate and neuroendocrine cancers. The global market for radiopharmaceuticals was estimated at $6.1 billion in 2019\, and is projected to reach $12.6 billion by 2027. \nThe Blakes Breakfast Speaking Series is our longest-standing event series and one of our most popular. These breakfasts include presentations by local\, national\, and multinational life science companies and typically attract a cross-section of approximately 75 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake\, Cassels & Graydon LLP. \nSpeakers:\n\nNoël Brown\, Managing Director & Head of U.S. Biotechnology Investment Banking\, RBC Capital Markets\nKathryn Hayashi\, President & CEO\, TRIUMF Innovations\nDr. Lana Janes\, Venture Partner at adMare BioInnovations\, Interim CEO at Abdera Therapeutics\nCody Shirriff\, CEO & Founder\, Serenity Bioworks\n\nEvent Details:\nDate: October 7\, 2021 \nTime: 9:30 AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/blakes-breakfast-speaking-series-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Blakes-Breakfast-Main-Image-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T093000
DTEND;TZID=America/Vancouver:20211007T110000
DTSTAMP:20260406T072721
CREATED:20211004T165740Z
LAST-MODIFIED:20211004T165740Z
UID:28058-1633599000-1633604400@scienceinvancouver.com
SUMMARY:Blakes Breakfast Speaking Series
DESCRIPTION:A new class of drugs is emerging to expand the spectrum of treatments for cancer\, called radiopharmaceuticals\, which deliver radiation directly and specifically to cancer cells.  These drugs contain radioactive isotopes and can be used as both diagnostic and therapeutic agents. \nTargeting radiation therapy at the cellular level has the potential to reduce the risk of both short-term and long-term side effects of treatment\, while proving effective at killing even the small clusters of cancer cells throughout the body. \nReduced side effects and precision delivery are driving the interest and high growth in this new generation of radiopharmaceuticals. A number of new therapies are emerging\, including using lutetium-177 to treat prostate and neuroendocrine cancers. The global market for radiopharmaceuticals was estimated at $6.1 billion in 2019\, and is projected to reach $12.6 billion by 2027. \nThe Blakes Breakfast Speaking Series is our longest-standing event series and one of our most popular. These breakfasts include presentations by local\, national\, and multinational life science companies and typically attract a cross-section of approximately 75 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake\, Cassels & Graydon LLP. \nSpeakers:\n\nNoël Brown\, Managing Director & Head of U.S. Biotechnology Investment Banking\, RBC Capital Markets\nKathryn Hayashi\, President & CEO\, TRIUMF Innovations\nDr. Lana Janes\, Venture Partner at adMare BioInnovations\, Interim CEO at Abdera Therapeutics\nCody Shirriff\, CEO & Founder\, Serenity Bioworks\n\nEvent Details:\nDate: October 7\, 2021 \nTime: 9:30 AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/blakes-breakfast-speaking-series-3/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Blakes-Breakfast-Main-Image-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T093000
DTEND;TZID=America/Vancouver:20211007T110000
DTSTAMP:20260406T072721
CREATED:20211004T165740Z
LAST-MODIFIED:20211004T165740Z
UID:31141-1633599000-1633604400@scienceinvancouver.com
SUMMARY:Blakes Breakfast Speaking Series
DESCRIPTION:A new class of drugs is emerging to expand the spectrum of treatments for cancer\, called radiopharmaceuticals\, which deliver radiation directly and specifically to cancer cells.  These drugs contain radioactive isotopes and can be used as both diagnostic and therapeutic agents. \nTargeting radiation therapy at the cellular level has the potential to reduce the risk of both short-term and long-term side effects of treatment\, while proving effective at killing even the small clusters of cancer cells throughout the body. \nReduced side effects and precision delivery are driving the interest and high growth in this new generation of radiopharmaceuticals. A number of new therapies are emerging\, including using lutetium-177 to treat prostate and neuroendocrine cancers. The global market for radiopharmaceuticals was estimated at $6.1 billion in 2019\, and is projected to reach $12.6 billion by 2027. \nThe Blakes Breakfast Speaking Series is our longest-standing event series and one of our most popular. These breakfasts include presentations by local\, national\, and multinational life science companies and typically attract a cross-section of approximately 75 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake\, Cassels & Graydon LLP. \nSpeakers:\n\nNoël Brown\, Managing Director & Head of U.S. Biotechnology Investment Banking\, RBC Capital Markets\nKathryn Hayashi\, President & CEO\, TRIUMF Innovations\nDr. Lana Janes\, Venture Partner at adMare BioInnovations\, Interim CEO at Abdera Therapeutics\nCody Shirriff\, CEO & Founder\, Serenity Bioworks\n\nEvent Details:\nDate: October 7\, 2021 \nTime: 9:30 AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/blakes-breakfast-speaking-series-4/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Blakes-Breakfast-Main-Image-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T093000
DTEND;TZID=America/Vancouver:20211007T110000
DTSTAMP:20260406T072721
CREATED:20211004T165740Z
LAST-MODIFIED:20211004T165740Z
UID:32601-1633599000-1633604400@scienceinvancouver.com
SUMMARY:Blakes Breakfast Speaking Series
DESCRIPTION:A new class of drugs is emerging to expand the spectrum of treatments for cancer\, called radiopharmaceuticals\, which deliver radiation directly and specifically to cancer cells.  These drugs contain radioactive isotopes and can be used as both diagnostic and therapeutic agents. \nTargeting radiation therapy at the cellular level has the potential to reduce the risk of both short-term and long-term side effects of treatment\, while proving effective at killing even the small clusters of cancer cells throughout the body. \nReduced side effects and precision delivery are driving the interest and high growth in this new generation of radiopharmaceuticals. A number of new therapies are emerging\, including using lutetium-177 to treat prostate and neuroendocrine cancers. The global market for radiopharmaceuticals was estimated at $6.1 billion in 2019\, and is projected to reach $12.6 billion by 2027. \nThe Blakes Breakfast Speaking Series is our longest-standing event series and one of our most popular. These breakfasts include presentations by local\, national\, and multinational life science companies and typically attract a cross-section of approximately 75 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake\, Cassels & Graydon LLP. \nSpeakers:\n\nNoël Brown\, Managing Director & Head of U.S. Biotechnology Investment Banking\, RBC Capital Markets\nKathryn Hayashi\, President & CEO\, TRIUMF Innovations\nDr. Lana Janes\, Venture Partner at adMare BioInnovations\, Interim CEO at Abdera Therapeutics\nCody Shirriff\, CEO & Founder\, Serenity Bioworks\n\nEvent Details:\nDate: October 7\, 2021 \nTime: 9:30 AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/blakes-breakfast-speaking-series-5/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Blakes-Breakfast-Main-Image-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T120000
DTEND;TZID=America/Vancouver:20211007T230000
DTSTAMP:20260406T072721
CREATED:20210920T025525Z
LAST-MODIFIED:20210920T025525Z
UID:18377-1633608000-1633647600@scienceinvancouver.com
SUMMARY:CHÉOS Lunch and Learn: Modernizing Clinical Trial Regulations
DESCRIPTION:Presented by CHÉOS Director of Regulatory Affairs & Quality Assurance\, Dana Nohynek\, this presentation will cover Health Canada’s current thinking on opportunities to enhance regulatory agility and support innovation through a flexible and risk-based framework.
URL:https://scienceinvancouver.com/event/cheos-lunch-and-learn-modernizing-clinical-trial-regulations/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T120000
DTEND;TZID=America/Vancouver:20211007T230000
DTSTAMP:20260406T072721
CREATED:20210920T025525Z
LAST-MODIFIED:20210920T025525Z
UID:26437-1633608000-1633647600@scienceinvancouver.com
SUMMARY:CHÉOS Lunch and Learn: Modernizing Clinical Trial Regulations
DESCRIPTION:Presented by CHÉOS Director of Regulatory Affairs & Quality Assurance\, Dana Nohynek\, this presentation will cover Health Canada’s current thinking on opportunities to enhance regulatory agility and support innovation through a flexible and risk-based framework.
URL:https://scienceinvancouver.com/event/cheos-lunch-and-learn-modernizing-clinical-trial-regulations-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T120000
DTEND;TZID=America/Vancouver:20211007T230000
DTSTAMP:20260406T072721
CREATED:20210920T025525Z
LAST-MODIFIED:20210920T025525Z
UID:28052-1633608000-1633647600@scienceinvancouver.com
SUMMARY:CHÉOS Lunch and Learn: Modernizing Clinical Trial Regulations
DESCRIPTION:Presented by CHÉOS Director of Regulatory Affairs & Quality Assurance\, Dana Nohynek\, this presentation will cover Health Canada’s current thinking on opportunities to enhance regulatory agility and support innovation through a flexible and risk-based framework.
URL:https://scienceinvancouver.com/event/cheos-lunch-and-learn-modernizing-clinical-trial-regulations-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T120000
DTEND;TZID=America/Vancouver:20211007T230000
DTSTAMP:20260406T072721
CREATED:20210920T025525Z
LAST-MODIFIED:20210920T025525Z
UID:31135-1633608000-1633647600@scienceinvancouver.com
SUMMARY:CHÉOS Lunch and Learn: Modernizing Clinical Trial Regulations
DESCRIPTION:Presented by CHÉOS Director of Regulatory Affairs & Quality Assurance\, Dana Nohynek\, this presentation will cover Health Canada’s current thinking on opportunities to enhance regulatory agility and support innovation through a flexible and risk-based framework.
URL:https://scienceinvancouver.com/event/cheos-lunch-and-learn-modernizing-clinical-trial-regulations-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211007T120000
DTEND;TZID=America/Vancouver:20211007T230000
DTSTAMP:20260406T072721
CREATED:20210920T025525Z
LAST-MODIFIED:20210920T025525Z
UID:32595-1633608000-1633647600@scienceinvancouver.com
SUMMARY:CHÉOS Lunch and Learn: Modernizing Clinical Trial Regulations
DESCRIPTION:Presented by CHÉOS Director of Regulatory Affairs & Quality Assurance\, Dana Nohynek\, this presentation will cover Health Canada’s current thinking on opportunities to enhance regulatory agility and support innovation through a flexible and risk-based framework.
URL:https://scienceinvancouver.com/event/cheos-lunch-and-learn-modernizing-clinical-trial-regulations-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211019T123000
DTEND;TZID=America/Vancouver:20211019T133000
DTSTAMP:20260406T072721
CREATED:20211014T200153Z
LAST-MODIFIED:20211018T202947Z
UID:18785-1634646600-1634650200@scienceinvancouver.com
SUMMARY:Seminar - Patrolling Monocyte Development and Regulation of Obesity\, Tumour Metastasis\, and Alzheimer’s Disease
DESCRIPTION:The University of British Columbia Department of Microbiology and Immunology presents a seminar by:\n\n\n\n\nJessica Silva\n\n\nPhD Candidate\n  \n\nentitled:\n\nSeminar – Patrolling Monocyte Development And Regulation Of Obesity\, Tumour Metastasis and Alzheimer’s Disease\n  \n\n\n\n\n \nSponsored by: The Department of Microbiology and Immunology \nPlease note that our seminars will be Hybrid (in-person & Zoom). The seminar will be in LSC3 but if you prefer to join via Zoom please contact parvin@mail.ubc.ca(link sends e-mail) for how to join!\n\n\n\nTuesday\, October 19\, 2021 – 12:30pm to 1:30pm\nLocation: \nLife Sciences Centre\, LSC 3\n2350 Health Sciences Mall\n\n\nHosted by \nDr. Ken Harder
URL:https://scienceinvancouver.com/event/seminar-patrolling-monocyte-development-and-regulation-of-obesity-tumour-metastasis-and-alzheimers-disease/
LOCATION:Life Sciences Centre\, 2350 Health Sciences Mall\, Vancouver
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211019T123000
DTEND;TZID=America/Vancouver:20211019T133000
DTSTAMP:20260406T072721
CREATED:20211014T200153Z
LAST-MODIFIED:20211014T200153Z
UID:26447-1634646600-1634650200@scienceinvancouver.com
SUMMARY:Seminar - Patrolling Monocyte Development and Regulation of Obesity\, Tumour Metastasis\, and Alzheimer’s Disease
DESCRIPTION:The University of British Columbia Department of Microbiology and Immunology presents a seminar by:\n\n\n\n\nJessica Silva\n\n\nPhD Candidate\n  \n\nentitled:\n\nSeminar – Patrolling Monocyte Development And Regulation Of Obesity\, Tumour Metastasis and Alzheimer’s Disease\n  \n\n\n\n\n \nSponsored by: The Department of Microbiology and Immunology \nPlease note that our seminars will be Hybrid (in-person & Zoom). The seminar will be in LSC3 but if you prefer to join via Zoom please contact parvin@mail.ubc.ca(link sends e-mail) for how to join!\n\n\n\nTuesday\, October 19\, 2021 – 12:30pm to 1:30pm\nLocation: \nLife Sciences Centre\, LSC 3\n2350 Health Sciences Mall\n\n\nHosted by \nDr. Ken Harder
URL:https://scienceinvancouver.com/event/seminar-patrolling-monocyte-development-and-regulation-of-obesity-tumour-metastasis-and-alzheimers-disease-2/
LOCATION:Life Sciences Centre\, 2350 Health Sciences Mall\, Vancouver
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211019T123000
DTEND;TZID=America/Vancouver:20211019T133000
DTSTAMP:20260406T072721
CREATED:20211014T200153Z
LAST-MODIFIED:20211014T200153Z
UID:28062-1634646600-1634650200@scienceinvancouver.com
SUMMARY:Seminar - Patrolling Monocyte Development and Regulation of Obesity\, Tumour Metastasis\, and Alzheimer’s Disease
DESCRIPTION:The University of British Columbia Department of Microbiology and Immunology presents a seminar by:\n\n\n\n\nJessica Silva\n\n\nPhD Candidate\n  \n\nentitled:\n\nSeminar – Patrolling Monocyte Development And Regulation Of Obesity\, Tumour Metastasis and Alzheimer’s Disease\n  \n\n\n\n\n \nSponsored by: The Department of Microbiology and Immunology \nPlease note that our seminars will be Hybrid (in-person & Zoom). The seminar will be in LSC3 but if you prefer to join via Zoom please contact parvin@mail.ubc.ca(link sends e-mail) for how to join!\n\n\n\nTuesday\, October 19\, 2021 – 12:30pm to 1:30pm\nLocation: \nLife Sciences Centre\, LSC 3\n2350 Health Sciences Mall\n\n\nHosted by \nDr. Ken Harder
URL:https://scienceinvancouver.com/event/seminar-patrolling-monocyte-development-and-regulation-of-obesity-tumour-metastasis-and-alzheimers-disease-3/
LOCATION:Life Sciences Centre\, 2350 Health Sciences Mall\, Vancouver
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211019T123000
DTEND;TZID=America/Vancouver:20211019T133000
DTSTAMP:20260406T072721
CREATED:20211014T200153Z
LAST-MODIFIED:20211014T200153Z
UID:31145-1634646600-1634650200@scienceinvancouver.com
SUMMARY:Seminar - Patrolling Monocyte Development and Regulation of Obesity\, Tumour Metastasis\, and Alzheimer’s Disease
DESCRIPTION:The University of British Columbia Department of Microbiology and Immunology presents a seminar by:\n\n\n\n\nJessica Silva\n\n\nPhD Candidate\n  \n\nentitled:\n\nSeminar – Patrolling Monocyte Development And Regulation Of Obesity\, Tumour Metastasis and Alzheimer’s Disease\n  \n\n\n\n\n \nSponsored by: The Department of Microbiology and Immunology \nPlease note that our seminars will be Hybrid (in-person & Zoom). The seminar will be in LSC3 but if you prefer to join via Zoom please contact parvin@mail.ubc.ca(link sends e-mail) for how to join!\n\n\n\nTuesday\, October 19\, 2021 – 12:30pm to 1:30pm\nLocation: \nLife Sciences Centre\, LSC 3\n2350 Health Sciences Mall\n\n\nHosted by \nDr. Ken Harder
URL:https://scienceinvancouver.com/event/seminar-patrolling-monocyte-development-and-regulation-of-obesity-tumour-metastasis-and-alzheimers-disease-4/
LOCATION:Life Sciences Centre\, 2350 Health Sciences Mall\, Vancouver
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211019T123000
DTEND;TZID=America/Vancouver:20211019T133000
DTSTAMP:20260406T072721
CREATED:20211014T200153Z
LAST-MODIFIED:20211014T200153Z
UID:32605-1634646600-1634650200@scienceinvancouver.com
SUMMARY:Seminar - Patrolling Monocyte Development and Regulation of Obesity\, Tumour Metastasis\, and Alzheimer’s Disease
DESCRIPTION:The University of British Columbia Department of Microbiology and Immunology presents a seminar by:\n\n\n\n\nJessica Silva\n\n\nPhD Candidate\n  \n\nentitled:\n\nSeminar – Patrolling Monocyte Development And Regulation Of Obesity\, Tumour Metastasis and Alzheimer’s Disease\n  \n\n\n\n\n \nSponsored by: The Department of Microbiology and Immunology \nPlease note that our seminars will be Hybrid (in-person & Zoom). The seminar will be in LSC3 but if you prefer to join via Zoom please contact parvin@mail.ubc.ca(link sends e-mail) for how to join!\n\n\n\nTuesday\, October 19\, 2021 – 12:30pm to 1:30pm\nLocation: \nLife Sciences Centre\, LSC 3\n2350 Health Sciences Mall\n\n\nHosted by \nDr. Ken Harder
URL:https://scienceinvancouver.com/event/seminar-patrolling-monocyte-development-and-regulation-of-obesity-tumour-metastasis-and-alzheimers-disease-5/
LOCATION:Life Sciences Centre\, 2350 Health Sciences Mall\, Vancouver
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211020T100000
DTEND;TZID=America/Vancouver:20211020T110000
DTSTAMP:20260406T072721
CREATED:20211004T165959Z
LAST-MODIFIED:20211004T165959Z
UID:18635-1634724000-1634727600@scienceinvancouver.com
SUMMARY:From Discovery to Market: The Role of IP Strategy in Drug Development
DESCRIPTION:Drug development in Canada is a long and complex process\, and the market is competitive. At the heart of drug development is intellectual property (IP). Life sciences companies who develop an IP strategy at the outset of a new project have a competitive advantage by creating value\, generating revenue\, and obtaining market intelligence. Without a strategy\, companies risk losing IP assets\, missing out on investment opportunities\, and being exposed to competition. \nOn Wednesday\, October 20\, join a panel of industry insiders who will discuss the key IP opportunities and strategies related to drug development in Canada. The panel will touch on everything from identifying intellectual property during R&D to the importance of freedom to operate analysis\, international filing strategies and portfolio management\, and of course\, the unique industry challenges brought to light due to the COVID-19 pandemic. \n\n\n\n\n\n\nSpeakers:  \n\nBrian Kingwell\, Partner\, Gowling WLG\nIsabelle Riedl\, Senior Supervisor\, Intellectual Property\, Medicago\nSonia Ziesche\, Principal\, Patent Agent\, Gowling WLG\n\n\n\n\n\n\n\n\n\n\n\n\nEvent Details:\n\n\n\n\n\n\n\n\n\n\n\nDate: Wednesday\, October 20\, 2021 \nTime: 10:00AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/from-discovery-to-market-the-role-of-ip-strategy-in-drug-development/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Gowling-Event-Images-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211020T100000
DTEND;TZID=America/Vancouver:20211020T110000
DTSTAMP:20260406T072721
CREATED:20211004T165959Z
LAST-MODIFIED:20211004T165959Z
UID:26444-1634724000-1634727600@scienceinvancouver.com
SUMMARY:From Discovery to Market: The Role of IP Strategy in Drug Development
DESCRIPTION:Drug development in Canada is a long and complex process\, and the market is competitive. At the heart of drug development is intellectual property (IP). Life sciences companies who develop an IP strategy at the outset of a new project have a competitive advantage by creating value\, generating revenue\, and obtaining market intelligence. Without a strategy\, companies risk losing IP assets\, missing out on investment opportunities\, and being exposed to competition. \nOn Wednesday\, October 20\, join a panel of industry insiders who will discuss the key IP opportunities and strategies related to drug development in Canada. The panel will touch on everything from identifying intellectual property during R&D to the importance of freedom to operate analysis\, international filing strategies and portfolio management\, and of course\, the unique industry challenges brought to light due to the COVID-19 pandemic. \n\n\n\n\n\n\nSpeakers:  \n\nBrian Kingwell\, Partner\, Gowling WLG\nIsabelle Riedl\, Senior Supervisor\, Intellectual Property\, Medicago\nSonia Ziesche\, Principal\, Patent Agent\, Gowling WLG\n\n\n\n\n\n\n\n\n\n\n\n\nEvent Details:\n\n\n\n\n\n\n\n\n\n\n\nDate: Wednesday\, October 20\, 2021 \nTime: 10:00AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/from-discovery-to-market-the-role-of-ip-strategy-in-drug-development-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Gowling-Event-Images-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211020T100000
DTEND;TZID=America/Vancouver:20211020T110000
DTSTAMP:20260406T072721
CREATED:20211004T165959Z
LAST-MODIFIED:20211004T165959Z
UID:28059-1634724000-1634727600@scienceinvancouver.com
SUMMARY:From Discovery to Market: The Role of IP Strategy in Drug Development
DESCRIPTION:Drug development in Canada is a long and complex process\, and the market is competitive. At the heart of drug development is intellectual property (IP). Life sciences companies who develop an IP strategy at the outset of a new project have a competitive advantage by creating value\, generating revenue\, and obtaining market intelligence. Without a strategy\, companies risk losing IP assets\, missing out on investment opportunities\, and being exposed to competition. \nOn Wednesday\, October 20\, join a panel of industry insiders who will discuss the key IP opportunities and strategies related to drug development in Canada. The panel will touch on everything from identifying intellectual property during R&D to the importance of freedom to operate analysis\, international filing strategies and portfolio management\, and of course\, the unique industry challenges brought to light due to the COVID-19 pandemic. \n\n\n\n\n\n\nSpeakers:  \n\nBrian Kingwell\, Partner\, Gowling WLG\nIsabelle Riedl\, Senior Supervisor\, Intellectual Property\, Medicago\nSonia Ziesche\, Principal\, Patent Agent\, Gowling WLG\n\n\n\n\n\n\n\n\n\n\n\n\nEvent Details:\n\n\n\n\n\n\n\n\n\n\n\nDate: Wednesday\, October 20\, 2021 \nTime: 10:00AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/from-discovery-to-market-the-role-of-ip-strategy-in-drug-development-3/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Gowling-Event-Images-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211020T100000
DTEND;TZID=America/Vancouver:20211020T110000
DTSTAMP:20260406T072721
CREATED:20211004T165959Z
LAST-MODIFIED:20211004T165959Z
UID:31142-1634724000-1634727600@scienceinvancouver.com
SUMMARY:From Discovery to Market: The Role of IP Strategy in Drug Development
DESCRIPTION:Drug development in Canada is a long and complex process\, and the market is competitive. At the heart of drug development is intellectual property (IP). Life sciences companies who develop an IP strategy at the outset of a new project have a competitive advantage by creating value\, generating revenue\, and obtaining market intelligence. Without a strategy\, companies risk losing IP assets\, missing out on investment opportunities\, and being exposed to competition. \nOn Wednesday\, October 20\, join a panel of industry insiders who will discuss the key IP opportunities and strategies related to drug development in Canada. The panel will touch on everything from identifying intellectual property during R&D to the importance of freedom to operate analysis\, international filing strategies and portfolio management\, and of course\, the unique industry challenges brought to light due to the COVID-19 pandemic. \n\n\n\n\n\n\nSpeakers:  \n\nBrian Kingwell\, Partner\, Gowling WLG\nIsabelle Riedl\, Senior Supervisor\, Intellectual Property\, Medicago\nSonia Ziesche\, Principal\, Patent Agent\, Gowling WLG\n\n\n\n\n\n\n\n\n\n\n\n\nEvent Details:\n\n\n\n\n\n\n\n\n\n\n\nDate: Wednesday\, October 20\, 2021 \nTime: 10:00AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/from-discovery-to-market-the-role-of-ip-strategy-in-drug-development-4/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Gowling-Event-Images-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211020T100000
DTEND;TZID=America/Vancouver:20211020T110000
DTSTAMP:20260406T072721
CREATED:20211004T165959Z
LAST-MODIFIED:20211004T165959Z
UID:32602-1634724000-1634727600@scienceinvancouver.com
SUMMARY:From Discovery to Market: The Role of IP Strategy in Drug Development
DESCRIPTION:Drug development in Canada is a long and complex process\, and the market is competitive. At the heart of drug development is intellectual property (IP). Life sciences companies who develop an IP strategy at the outset of a new project have a competitive advantage by creating value\, generating revenue\, and obtaining market intelligence. Without a strategy\, companies risk losing IP assets\, missing out on investment opportunities\, and being exposed to competition. \nOn Wednesday\, October 20\, join a panel of industry insiders who will discuss the key IP opportunities and strategies related to drug development in Canada. The panel will touch on everything from identifying intellectual property during R&D to the importance of freedom to operate analysis\, international filing strategies and portfolio management\, and of course\, the unique industry challenges brought to light due to the COVID-19 pandemic. \n\n\n\n\n\n\nSpeakers:  \n\nBrian Kingwell\, Partner\, Gowling WLG\nIsabelle Riedl\, Senior Supervisor\, Intellectual Property\, Medicago\nSonia Ziesche\, Principal\, Patent Agent\, Gowling WLG\n\n\n\n\n\n\n\n\n\n\n\n\nEvent Details:\n\n\n\n\n\n\n\n\n\n\n\nDate: Wednesday\, October 20\, 2021 \nTime: 10:00AM – 11:00AM PT \nPlatform: Zoom \nTickets: Free for LSBC members & $25 for LSBC non-members
URL:https://scienceinvancouver.com/event/from-discovery-to-market-the-role-of-ip-strategy-in-drug-development-5/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/10/Gowling-Event-Images-1.png
END:VEVENT
END:VCALENDAR